ADC Therapeutics.

Confronting cancer with the full potential of our science.

ADC Therapeutics is a commercial-stage biotechnology company dedicated to delivering next-generation PBD-Based ADCs for those affected by cancer. With a deep understanding of ADC technology and of the oncology treatment landscape, ADC Therapeutics intends to address significant unmet medical needs and improve outcomes for those with difficult-to-treat cancers.

Founded in 2011, ADC Therapeutics is based in Lausanne, Switzerland, with operations in London (R&D), New Jersey (Clinical and Commercial) and the San Francisco Bay Area (CMC).

“Providing unique, targeted therapies for those in need isn’t just a priority, it’s a privilege.”
— Chris Martin, CEO and Cofounder, ADC Therapeutics

Chris Martin
Corporate Video

Our History

2011
ADC Therapeutics founded as a spin-off from Spirogen Ltd, which was founded in 2000 and was an early innovator in PBD-based ADC research
2015
ADC Therapeutics cofounder Chris Martin appointed CEO
2016
First patient enrolled in phase 1 clinical trial of lead investigational compound loncastuximab tesirine-lpyl, targeting CD19 in positive B-cell non-Hodgkin lymphoma
2019
First patient enrolled in phase 2 clinical trial of investigational compound camidanlumab tesirine, targeting CD25 in relapsed or refractory Hodgkin lymphoma
2020
Ron Squarer, former CEO of Array BioPharma, Inc, appointed Chairman of the Board
$267-million IPO with the NYSE
ticker “ADCT”
Announced pivotal phase 2 clinical trial of CD19-targeted, lead investigational compound loncastuximab tesirine-lpyl
Biologics license application (BLA) submission for CD19-targeted, lead investigational compound loncastuximab tesirine-lpyl
Biologics license application (BLA) acceptance with priority review for CD19-targeted, lead investigational compound loncastuximab tesirine-lpyl
2021
CD19-targeted, lead investigational compound loncastuximab tesirine-lpyl receives FDA approval
2021
  • April
    CD19-targeted, lead investigational compound loncastuximab tesirine-lpyl receives FDA approval
2020
  • November
    Biologics license application (BLA) acceptance with priority review for CD19-targeted, lead investigational compound loncastuximab tesirine-lpyl
  • September
    Biologics license application (BLA) submission for CD19-targeted, lead investigational compound loncastuximab tesirine-lpyl
  • June
    Announced pivotal phase 2 clinical trial of CD19-targeted, lead investigational compound loncastuximab tesirine-lpyl
  • May
    $267-million IPO with the NYSE ticker “ADCT”
  • March
    Ron Squarer, former CEO of Array BioPharma, Inc, appointed Chairman of the Board
2019
  • October
    First patient enrolled in phase 2 clinical trial of investigational compound camidanlumab tesirine, targeting CD25 in relapsed or refractory Hodgkin lymphoma
2016
  • March
    First patient enrolled in phase 1 clinical trial of lead investigational compound loncastuximab tesirine-lpyl, targeting CD19 in positive B-cell non-Hodgkin lymphoma
2015
  • June
    ADC Therapeutics cofounder Chris Martin appointed CEO
2011
  • June
    ADC Therapeutics founded as a spin-off from Spirogen Ltd, which was founded in 2000 and was an early innovator in PBD-based ADC research

ADC, antibody-drug conjugate; PBD, pyrrolobenzodiazepine.

Our Purpose

Our mission, vision, and values form the foundation of ADC Therapeutics and provide guidance for all future endeavors. These foundational pillars are also a meaningful expression of the company’s dedication to helping those with difficult-to-treat cancers.

Our Mission

We are confronting cancer with the full potential of our science, bringing unique, targeted therapies and hope to patients and their families.

Our Vision

We will transform what patients and their families can expect from cancer therapy.

Our Values

PATIENTS: Patients and their families are at the core of everything we do; they inspire our scientific creativity and innovation

CHARACTER: We are open, honest, trustworthy, and respectful in our words and actions

URGENCY: We operate with a sense of urgency in all that we do

PEOPLE: We encourage individuals to continually learn and grow so that everyone can work at their full potential

Our Leadership
and the Board of Directors

Partnering

At ADC Therapeutics, we are on a mission to confront cancer with the full potential of our science to bring unique, targeted therapies and hope to patients and their families. To help support this mission, we actively seek innovative collaborations and strategic business development opportunities.

To start the conversation about partnering with ADC Therapeutics, please contact us at partnering@adctherapeutics.com.